EurekaMag.com logo
+ Site Statistics
References:
53,214,146
Abstracts:
29,074,682
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Platelet sensitivity to antiaggregatory prostaglandins e 1 d 2 and i 2 and in patients with peripheral vascular disease



Platelet sensitivity to antiaggregatory prostaglandins e 1 d 2 and i 2 and in patients with peripheral vascular disease



American Journal of Hematology 19(1): 13-20



Platelet sensitivity to antiaggregatory prostaglandins (PGI2, PGE1, PGD2) was studied in 143 patients (122 male) with angiographically proven peripheral vascular disease and compared with age-matched clinically normal controls. Patients had a significantly lower platelet sensitivity to PgI2, PGE1, and PGD2 than controls. Clinical stages had no significant influence on the platelet sensitivity to PGI2 and PGE1. Patients with stage IIa had a lower sensitivity to PGD2 than patients with stage IV, the difference not being significant. Analyzing the influence of risk factors like diabetes, hyperlipoproteinemia, or smoking, there seemed to be an inverse relation between risk factors and platelet senstivity to PGI2 and PGE1. Smokers especially, together with smokers exhibiting an additional risk factor, exhibited the highest prostaglandin consumption (PGI2, PGE1) and therefore the lowest platelet sensitivity. The differences were not significant. There was a significant correlation between platelet sensitivity to PGI2 and PGE1, whereas this was not the case between the respective sensitivities to PGI2 and PGD2. Both these prostaglandins (PGI2, PGE1) share the same receptor on the platelet surface, whereas PGD2 than its own receptor.

(PDF 0-2 workdays service: $29.90)

Accession: 006135054

Download citation: RISBibTeXText



Related references

Platelet sensitivity to antiaggregatory prostaglandins (PGE1,D2,I2) in patients with peripheral vascular disease. American Journal of Hematology 19(1): 13-19, 1985

Value of platelet sensitivity to antiaggregatory prostaglandins (PGI2, PGE1, PGD2) in 50 patients with myocardial infarction at young age. Prostaglandins and Medicine 7(2): 125-132, 1981

Age dependent behaviour of platelet sensitivity for antiaggregatory prostaglandins. Wiener tierarztliche Monatsschrift8(10): 332-335, 1981

Influence of prostaglandins on in vivo platelet function in patients with peripheral vascular disease pvd. Vasa Supplementum (15): 29, 1986

Passive smoking severely decreases platelet sensitivity to antiaggregatory prostaglandins. Lancet 2(8294): 392-393, 1982

Platelet function and prostaglandins in patients with peripheral vascular disease treated with calcium dobesilate. Prostaglandins Leukotrienes & Medicine 29(1): 1-10, 1987

Hypertension and beneficial treatment with beta-blocking agents does not change the platelet sensitivity to the antiaggregatory prostaglandins. Prostaglandins, Leukotrienes, and Medicine 9(3): 301-305, 1982

Beraprost sodium, Procylin , Dorner Platelet antiaggregatory, treatment of pulmonary hypertension, treatment of peripheral vascular disease EN 116067. Drugs Of The Future. 25(11): 1179, Ember, 2000

Plasma factor and platelet sensitivity to prostacyclin in patients with peripheral vascular disease before and after treatment with a combination of a cyclooxygenase and a phosphodiesterase inhibitor. Prostaglandins, Leukotrienes, and Medicine 15(2): 241-250, 1984

Diminished platelet yield and enhanced platelet aggregability in platelet-rich plasma of peripheral vascular disease patients. International Angiology 13(3): 202-207, 1994

Vascular prostacyclin synthesis platelet sensitivity plasma factors and platelet function in patients with peripheral occlusive arteriopathy with and without diabetes mellitus. Noseda, G , B Lewis And R Paoletti (Ed ) Diet And Drugs in Atherosclerosis; European Atherosclerosis Group Meeting, Lugano, Switzerland, Sept 1979 Xix+327p Raven Press: New York, N Y , Usa Illus P93-96, 1980

Platelet activation in patients with peripheral vascular disease: reproducibility and comparability of platelet markers. Thrombosis Research 129(1): 50-55, 2012

Platelet-associated factor XIII as a marker of platelet activation in patients with peripheral vascular disease. Arteriosclerosis and Thrombosis 13(6): 857-862, 1993

In vivo modulation of platelet deposition on human atherosclerotic lesions by various antiaggregatory prostaglandins. Folia Haematologica 115(4): 443-446, 1988

Diminished bonding sites for antiaggregatory prostaglandins on the blood platelet membranes of type i diabetics. Acta Medica Austriaca 14(SPEC ISSUE): 66, 1987